What You Should Know:
– Cellino, a Cambridge, MA-based personalized regenerative medicine company developing an AI-guided laser editing platform for autologous cell-based therapies, today announced the closing of a $16M Seed financing round. The round was co-led by The Engine and Khosla Ventures, with participation from Humboldt Fund and 8VC.
– The company’s platform solves a time-consuming, major bottleneck of developing drugs that rely on cell therapy, having to remove stem cells by hand, individually, during the manufacturing process. CEO Nabiha Saklayen founded Cellino in 2017 while still in her mid-20s (Forbes’ 30 Under 30 list and MIT Tech Review’s 35 Innovators Under 35 list).
– The $16M seed financing will further advance Cellino’s technology that uses artificial intelligence and a personalized tissue and cell platform and ultimately seeks to generate autologous induced pluripotent stem cells at scale.
